Sharon Mates is Chairman and Chief Executive Officer of Intra-Cellular Therapies, Inc. (ITCI). The company reported total compensation of $10,086,413 for fiscal year 2023.
| Salary | $891,653 |
|---|---|
| Bonus | $1,426,645 |
| Stock awards | $7,749,984 |
| Option awards | $0 |
| Non-equity incentive plan | $0 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $18,131 |
| Total | $10,086,413 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Intra-Cellular Therapies, Inc. filed April 29, 2024, accession 0001628280-24-018986.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2023 | Chairman and Chief Executive Officer | $891,653 | $1,426,645 | $7,749,984 | $0 | $0 | $0 | $18,131 | $10,086,413 |
| FY2022 | Chairman and Chief Executive Officer | $849,193 | $1,358,709 | $4,899,997 | $2,099,991 | $0 | $0 | $24,967 | $9,232,857 |
| FY2021 | Chairman and Chief Executive Officer | $793,638 | $1,428,548 | $3,500,012 | $1,499,978 | $0 | $0 | $23,767 | $7,245,943 |
Totals as disclosed in each year's own compensation disclosure for Intra-Cellular Therapies, Inc..
| Peer-group chief executive median | $12,951,082 |
|---|---|
| Difference from that median | $-2,864,669 |
| Percentile within the disclosed peer group | 29th |
| Peers with a disclosed figure | 17 |
Medians and percentiles are computed across the peer group Intra-Cellular Therapies, Inc. discloses in its own compensation disclosure.
| Named executive officer | Role | FY2023 total |
|---|---|---|
| Sharon Mates this page | Chairman and Chief Executive Officer | $10,086,413 |
| Mark Neumann | Executive Vice President, Chief Commercial Officer | $3,543,028 |
| Michael Halstead | President | $3,526,233 |
| Suresh Durgam | Executive Vice President, Chief Medical Officer | $3,511,175 |
| Lawrence Hineline | Senior Vice President of Finance, Chief Financial Officer, Treasurer and Assistant Secretary | $3,361,110 |
The company's named executive officers for fiscal year 2023, and what it reported for each. See the full Intra-Cellular Therapies, Inc. compensation brief.
Sharon Mates's compensation sits inside Intra-Cellular Therapies, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.
The Intra-Cellular Therapies, Inc. (ITCI) compensation brief